Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,983 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient.
Hastings RK, Openshaw MR, Vazquez M, Moreno-Cardenas AB, Fernandez-Garcia D, Martinson L, Kulbicki K, Primrose L, Guttery DS, Page K, Toghill B, Richards C, Thomas A, Tabernero J, Coombes RC, Ahmed S, Toledo RA, Shaw JA. Hastings RK, et al. Among authors: thomas a. Ann Oncol. 2021 May;32(5):681-684. doi: 10.1016/j.annonc.2021.02.007. Epub 2021 Feb 18. Ann Oncol. 2021. PMID: 33609721 Free article. No abstract available.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Höhler T, Kim JS, Hofheinz RD, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Iveson T, Vogel A, Zalcberg JR. Folprecht G, et al. Among authors: thomas a. Ann Oncol. 2016 Jul;27(7):1273-9. doi: 10.1093/annonc/mdw176. Epub 2016 Apr 18. Ann Oncol. 2016. PMID: 27091810 Free article. Clinical Trial.
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium; Swanton C. Abbosh C, et al. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Nature. 2017. PMID: 28445469 Free PMC article.
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, Nusrat N, Scotland M, Bhundia V, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Bajaj A, Richards C, Wells-Jordan P, Thomas A; MiST2 study group. Fennell DA, et al. Among authors: thomas a. Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11. Lancet Oncol. 2022. PMID: 35157829 Clinical Trial.
An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy.
Demetriou C, Abid N, Butterworth M, Lezina L, Sandhu P, Howells L, Powley IR, Pringle JH, Sidat Z, Qassid O, Purnell D, Kaushik M, Duckworth K, Hartshorn H, Thomas A, Shaw JA, MacFarlane M, Pritchard C, Miles GJ. Demetriou C, et al. Among authors: thomas a. Sci Rep. 2024 Jun 4;14(1):12833. doi: 10.1038/s41598-024-63170-0. Sci Rep. 2024. PMID: 38834809 Free PMC article.
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group. Fennell DA, et al. Among authors: thomas a. Lancet Respir Med. 2021 Jun;9(6):593-600. doi: 10.1016/S2213-2600(20)30390-8. Epub 2021 Jan 27. Lancet Respir Med. 2021. PMID: 33515503 Clinical Trial.
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
Zhang M, Bzura A, Baitei EY, Zhou Z, Spicer JB, Poile C, Rogel J, Branson A, King A, Barber S, Kamata T, Dzialo J, Harber J, Greystoke A, Nusrat N, Faulkner D, Sun Q, Nolan L, Hahne JC, Scotland M, Walter H, Darlison L, Morgan B, Bajaj A, Brookes C, Hollox EJ, Lubawska D, Jama M, Griffiths G, Nakas A, Kutywayo K, Luo JL, Klampatsa A, Cooper A, Halder K, Wells-Jordan P, Zhou H, Dudbridge F, Thomas A, Richards CJ, Pritchard C, Yang H, Barer M, Fennell DA. Zhang M, et al. Among authors: thomas a. Nat Commun. 2024 Aug 21;15(1):7187. doi: 10.1038/s41467-024-49842-5. Nat Commun. 2024. PMID: 39168966 Free PMC article. Clinical Trial.
9,983 results